HK1200056A1 - Compounds for treating spinal muscular atrophy - Google Patents
Compounds for treating spinal muscular atrophyInfo
- Publication number
- HK1200056A1 HK1200056A1 HK15100611.2A HK15100611A HK1200056A1 HK 1200056 A1 HK1200056 A1 HK 1200056A1 HK 15100611 A HK15100611 A HK 15100611A HK 1200056 A1 HK1200056 A1 HK 1200056A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- muscular atrophy
- spinal muscular
- treating spinal
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261605487P | 2012-03-01 | 2012-03-01 | |
PCT/US2013/028131 WO2013130689A1 (fr) | 2012-03-01 | 2013-02-28 | Composés pour le traitement de l'amyotrophie spinale |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1200056A1 true HK1200056A1 (en) | 2015-07-31 |
Family
ID=49083256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15100611.2A HK1200056A1 (en) | 2012-03-01 | 2015-01-20 | Compounds for treating spinal muscular atrophy |
Country Status (11)
Country | Link |
---|---|
US (1) | US9371336B2 (fr) |
EP (1) | EP2819519B1 (fr) |
JP (1) | JP6092264B2 (fr) |
KR (1) | KR102099997B1 (fr) |
CN (1) | CN104302181B (fr) |
BR (1) | BR112014021531B1 (fr) |
CA (1) | CA2865957C (fr) |
EA (1) | EA029155B1 (fr) |
HK (1) | HK1200056A1 (fr) |
MX (1) | MX352962B (fr) |
WO (1) | WO2013130689A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2797592B1 (fr) | 2011-12-30 | 2019-08-28 | PTC Therapeutics, Inc. | Composés de traitement d'une amyotrophie spinale |
WO2013112788A1 (fr) | 2012-01-26 | 2013-08-01 | Ptc Therapeutics, Inc. | Composés destinés à traiter l'amyotrophie spinale |
EP2812004B1 (fr) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Composés destinés au traitement de l'amyotrophie spinale |
BR112014023483B1 (pt) | 2012-03-23 | 2022-05-10 | Ptc Therapeutics, Inc | Composto e seu uso, composição farmacêutica e seu uso |
JP2016503051A (ja) * | 2012-12-24 | 2016-02-01 | ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド | ナンセンス変異に起因する遺伝性疾患を治療する作用剤、及びこれを同定する方法 |
EP3035935B1 (fr) | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Composés utiles dans la prévention et le traitement du cancer |
EP3082820B1 (fr) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Procédés pour moduler la quantité de transcrits d'arn |
EP3310169B1 (fr) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Procédés de modulation de l'épissage de l'arn |
EP3133065A1 (fr) | 2015-08-21 | 2017-02-22 | Merck Patent GmbH | Composés de dispositifs optiquement actifs |
JP2019500352A (ja) | 2015-12-10 | 2019-01-10 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病の治療方法 |
MX2019005588A (es) | 2016-11-28 | 2019-10-15 | Ptc Therapeutics Inc | Metodos para modular corte y empalme de arn. |
EP3363793A1 (fr) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Composés hydrophobes pour dispositifs optiquement actifs |
EP3363786A1 (fr) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Composés de dispositifs optiquement actifs |
BR112019025740A2 (pt) | 2017-06-05 | 2020-06-23 | Ptc Therapeutics, Inc. | Compostos para tratar a doença de huntington |
AU2018284853A1 (en) | 2017-06-14 | 2019-12-19 | Ptc Therapeutics, Inc. | Methods for modifying RNA splicing |
US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
CA3067592A1 (fr) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methodes de traitement de la maladie de huntington |
KR102636383B1 (ko) | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
MX2020009957A (es) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
WO2020005882A1 (fr) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Composés hétéroaryles pour le traitement de la maladie de huntington |
US11858941B2 (en) | 2018-06-27 | 2024-01-02 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
WO2020163405A1 (fr) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Procédés et compositions pour moduler l'épissage |
EP3920928A4 (fr) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | Procédés et compositions pour moduler l'épissage |
US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
CN111116460A (zh) * | 2019-12-31 | 2020-05-08 | 阿里生物新材料(常州)有限公司 | 一种2-氯-4-羟基吡啶-3-甲醛氢溴酸盐的合成方法 |
BR112022023523A2 (pt) | 2020-05-20 | 2023-01-17 | AMO Ireland | Derivados de azacumarina e azatiocumarina para uso em dispositivos opticamente ativos |
WO2023114539A1 (fr) * | 2021-12-17 | 2023-06-22 | Pretzel Therapeutics, Inc. | Modulateurs de polrmt de type amino chromén-2-ones |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
EP0640083A1 (fr) | 1992-05-13 | 1995-03-01 | E.I. Du Pont De Nemours And Company | Derives de pyrido 1,2-a]pyrimidinone substituee utiles comme fongicides |
US5597922A (en) * | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
AU5991699A (en) | 1998-09-21 | 2000-04-10 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
ES2286093T3 (es) | 2000-01-24 | 2007-12-01 | Astrazeneca Ab | Compuestos terapeuticos morfolino-sustituidos. |
GB0205281D0 (en) * | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
AU2003237492A1 (en) | 2002-06-10 | 2003-12-22 | Acadia Pharmaceuticals Inc. | Urotensin ii receptor modulators |
US20040105849A1 (en) | 2002-11-25 | 2004-06-03 | Kaloidis Antonia C. | Treatment for SMA disease |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
CA2528771A1 (fr) | 2003-06-20 | 2004-12-29 | Chiron Corporation | Composes de pyridino[1,2-a]pyrimidin-4-one servant d'agents anticancereux |
US20050046698A1 (en) | 2003-09-02 | 2005-03-03 | Knight Andrew Frederick | System and method for producing a selectable view of an object space |
WO2005046698A1 (fr) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Composes heterocycliques fusionnes |
ATE373659T1 (de) | 2004-05-04 | 2007-10-15 | Warner Lambert Co | Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel |
WO2006045096A2 (fr) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Flavanoides et isoflavanoides pour la prevention et le traitement de maladies cardio-vasculaires |
CA2595477A1 (fr) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Nouveaux derives de benzo[c]chromene heterocycliques utiles en tant que modulateurs des recepteurs aux oestrogenes |
AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
EP2215074B1 (fr) | 2007-09-27 | 2014-02-19 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Composés d'isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations |
WO2009151546A2 (fr) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Procédés de traitement d'une atrophie musculaire spinale |
WO2010019243A1 (fr) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Méthodes de traitement d’infections virales |
WO2011062853A1 (fr) | 2009-11-20 | 2011-05-26 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 de type quinolizidinone-carboxamide |
CN102812023A (zh) | 2010-01-13 | 2012-12-05 | 韩国巴斯德研究所 | 抗感染吡啶并(1,2-a)嘧啶类 |
EP2797592B1 (fr) | 2011-12-30 | 2019-08-28 | PTC Therapeutics, Inc. | Composés de traitement d'une amyotrophie spinale |
WO2013112788A1 (fr) | 2012-01-26 | 2013-08-01 | Ptc Therapeutics, Inc. | Composés destinés à traiter l'amyotrophie spinale |
EP2812004B1 (fr) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Composés destinés au traitement de l'amyotrophie spinale |
BR112014023483B1 (pt) | 2012-03-23 | 2022-05-10 | Ptc Therapeutics, Inc | Composto e seu uso, composição farmacêutica e seu uso |
-
2013
- 2013-02-28 CA CA2865957A patent/CA2865957C/fr active Active
- 2013-02-28 MX MX2014010406A patent/MX352962B/es active IP Right Grant
- 2013-02-28 EA EA201491617A patent/EA029155B1/ru not_active IP Right Cessation
- 2013-02-28 US US14/380,385 patent/US9371336B2/en active Active
- 2013-02-28 KR KR1020147027577A patent/KR102099997B1/ko active IP Right Grant
- 2013-02-28 EP EP13755032.3A patent/EP2819519B1/fr active Active
- 2013-02-28 WO PCT/US2013/028131 patent/WO2013130689A1/fr active Application Filing
- 2013-02-28 BR BR112014021531-6A patent/BR112014021531B1/pt active IP Right Grant
- 2013-02-28 JP JP2014560007A patent/JP6092264B2/ja active Active
- 2013-02-28 CN CN201380023259.1A patent/CN104302181B/zh active Active
-
2015
- 2015-01-20 HK HK15100611.2A patent/HK1200056A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2015509956A (ja) | 2015-04-02 |
KR102099997B1 (ko) | 2020-04-13 |
EP2819519A4 (fr) | 2015-09-02 |
JP6092264B2 (ja) | 2017-03-08 |
CN104302181A (zh) | 2015-01-21 |
CN104302181B (zh) | 2017-09-15 |
US20150166575A1 (en) | 2015-06-18 |
CA2865957C (fr) | 2020-02-11 |
MX352962B (es) | 2017-12-15 |
BR112014021531B1 (pt) | 2022-10-04 |
EA029155B1 (ru) | 2018-02-28 |
EP2819519A1 (fr) | 2015-01-07 |
BR112014021531A8 (pt) | 2021-06-15 |
WO2013130689A1 (fr) | 2013-09-06 |
CA2865957A1 (fr) | 2013-09-06 |
KR20140131384A (ko) | 2014-11-12 |
EP2819519B1 (fr) | 2019-10-23 |
BR112014021531A2 (pt) | 2017-06-20 |
EA201491617A1 (ru) | 2015-01-30 |
MX2014010406A (es) | 2015-03-10 |
US9371336B2 (en) | 2016-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL254045B (en) | Compounds for the treatment of spinal muscular atrophy | |
HK1202069A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1200056A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1202527A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1202059A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1215399A1 (zh) | 用於治療脊髓性肌萎縮的化合物 | |
HRP20181190T1 (hr) | SPOJEVI KOJI SU KORISNI ZA LIJEČENJE AIDS-a | |
EP2872493A4 (fr) | Composés utilisables en vue du traitement de l'amyotrophie spinale | |
IL262611A (en) | Treatment for lipodystrophy | |
IL253421B (en) | Compounds for the treatment of fibrosis (Leifat) | |
EP2828100A4 (fr) | Traitement de surface pour une surface d'implant | |
EP2921120A4 (fr) | Outil de traitement pour endoscope | |
EP2904994A4 (fr) | Orthèse du tronc | |
EP2664286A4 (fr) | Outil de traitement pour endoscope | |
GB201010359D0 (en) | Compounds for treating proliferative disorders | |
EP2916767A4 (fr) | Dispositifs de traitement du bruxisme | |
EP2745764A4 (fr) | Outil de traitement destiné à un endoscope | |
ZA201503005B (en) | Ingenol-derived compounds useful for treating cancer | |
GB201203180D0 (en) | Compounds for treating parvovirus infection | |
EP2926817A4 (fr) | Composition pharmaceutique stable pour le traitement de l'ostéoporose | |
HK1209040A1 (en) | Methods for treating vestibulotoxicity | |
EP2563353A4 (fr) | Composés pour traitement antifongique | |
GB201215527D0 (en) | Compounds for the treatment of muscular dystrophy | |
GB201009495D0 (en) | Compounds for treating proliferative disorders |